Poor
Not Aligned
Patient Risk:
Moderate
Summary
Several statements are only partially supported or unsupported by the provided label excerpts; multiple interaction/risk claims specifically about 'citrus' are not supported as written (label excerpt addresses grapefruit juice). Mechanism statement is supported. Liver monitoring/caution is supported generally, but the 'particularly in pre-existing liver disease' and 'bleeding' claims are not supported by provided sections.
Category Scores
Accurate Statements
Lipitor (atorvastatin) works by reducing the amount of low-density lipoprotein (LDL) cholesterol in the blood.
12.1 Mechanism of Action: 'LIPITOR lowers plasma cholesterol and lipoprotein levels... increasing the number of hepatic LDL receptors...'; and 'LIPITOR reduces total-C, LDL-C...'.
Unsupported Statements
Consuming orange juice with Lipitor increased the levels of atorvastatin in the blood by 25%.
No label excerpt provided supports orange juice or a 25% increase.
Research suggests that citrus can increase the levels of Lipitor in the blood, potentially leading to increased side effects.
The provided interaction excerpt addresses grapefruit juice (not 'citrus' broadly) and does not mention increased side effects.
The combination of Lipitor and citrus may increase the risk of bleeding, particularly in patients taking anticoagulant medications.
No provided label excerpt supports bleeding risk or an interaction with anticoagulants for citrus.
Citrus may increase the risk of muscle damage (myopathy) in patients taking Lipitor.
The provided label excerpt supports myopathy risk with certain interacting drugs, and grapefruit juice increases atorvastatin concentrations, but no provided excerpt states 'citrus' (or grapefruit specifically) increases myopathy risk.
The combination of Lipitor and citrus may increase the risk of liver damage, particularly in patients with pre-existing liver disease.
The provided label excerpt supports caution with substantial alcohol and/or history of liver disease, contraindications for active liver disease/unexplained persistent transaminase elevations, and recommendations for LFT monitoring, but it does not support a citrus/grapefruit-related increase in liver damage risk.
Contradictions
Important Omissions
The label excerpt only specifies grapefruit juice (with CYP3A4 inhibition) and notes increased plasma concentrations of atorvastatin, especially with excessive consumption (>1.2 liters/day), not general 'citrus' or orange juice.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Interaction-related claims about 'citrus' (orange juice) and bleeding risk are unsupported by the provided label excerpts and could mislead risk perception. The label excerpt does support increased atorvastatin concentrations with grapefruit juice, and supports statin-associated myopathy and liver enzyme monitoring generally.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Multiple food/beverage and risk claims are unsupported and incorrectly generalized (e.g., 'orange juice' and broad 'citrus' rather than label-specified grapefruit juice; unsupported bleeding risk; unsupported citrus-related myopathy/liver damage).
Suggested Improvement
Replace 'citrus/orange juice' claims with the label-supported statement that grapefruit juice components can inhibit CYP3A4 and increase atorvastatin plasma concentrations (especially with excessive intake >1.2 liters/day), and remove or rephrase bleeding and citrus-specific myopathy/liver damage claims unless supported elsewhere in the full label.